Impact of comorbidities on hemoglobin stability in chronic kidney disease patients on dialysis treated with C.E.R.A FRESH-PEF74134-en Camille BACHOT Impact of comorbidities on hemoglobin stability in chronic kidney disease patients on dialysis treated with C.E.R.A MIRIADE FRESH-PEF74134-en 74134 FRESH-PEF74134 NCT01974271 F. HOFFMANN-LA ROCHE AG Epidemiology France Portal (PEF) null ;Medical data center MIRCERA® Nephrology Chronic kidney disease Healthcare system determinants: Use of care Healthcare system determinants Primary objective: To describe in CKD patients on dialysis the impact of comorbidities* on hemoglobin stability** after 6 months of treatment with Mircera® in routine clinical practice * Patients’ comorbidities will be analyzed on the basis of the CCI. ** Hemoglobin stability is defined as a variation of +/- 1g/dL of hemoglobin level between the first Mircera® injection and the 6th month of treatment, without red blood cells transfusion during this period. Secondary objectives: - In the overall study population and in each subgroup of patients defined by a range of the Charlson comorbidity index (<=3, [4-5], [6-7], >=8): - - To describe baseline characteristics of the patients; - - To describe the monthly changes in hemoglobin level; - - To describe monthly Mircera® dose. - To describe patients’ vital status and all adverse events over the observation period with Mircera®; - To describe the hemoglobin stability after 6 months of treatment with Mircera®, according to subgroups of Liu comorbidity index (<=3; [4-6]; [7-9]; >=10); - To describe the proportion of patients with an Hb level within the range 10-12 g/dL with or without hemoglobin stability after 6 months of treatment with Mircera®, according to the subgroups of Charlson and Liu comorbidity indexes.null null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Inclusion criteria: - Patient aged 18 years or older; - CKD patient on hemodialysis or hemodiafiltration for at least 3 months; - Patient previously treated with an ESA; - Patient for whom the investigator decided to initiate a treatment with Mircera® for medical reasons; - Patient with last hemoglobin level within the range [10 – 12] g/dL before Mircera® initiation; - Patient having received oral and written information about the study, without any objections for the use of his/her personal data, and having signed a written informed consent form. Patients participating in a clinical trial on renal anemia at inclusion were excluded from study entry. Clinical dataBiological data CDISCGCP/GVP Health care consumption and services Other Through organizations (health services or institutions schools businesses etc.) [500-1000[ individuals Converting or copying information into a structured record Observational Study Observational Study Cohort study 636 Unknown Restricted access Access on specific project only